Microwave tomography helps identify effectiveness of breast cancer treatment
Microwave imaging may be a useful way to monitor the effectiveness of breast cancer treatment.
Microwave tomography may be able to identify the effectiveness of breast cancer treatments at an early stage, enabling treatments to be changed in cases where the patient is not responding.
That is according to a study from Dartmouth-Hitchcock Medical Centre and published in BioMed Central's open access journal Breast Cancer Research.
The research showed age, breast density and body mass index did not obscure the results, which can be an issue with the use of other imaging techniques.
In fact, regions of high conductivity corresponded to the tumours and low conductivity corresponded to normal tissues, painting a clear view of the progress of the cancer.
"By recalling patients for scans during their treatment, we found that we could actually see tumours shrinking in women who responded to chemotherapy," said Paul Meany, who led the study.
He added: "Microwave tomography could therefore be used to identify women who are not responding to initial treatment and their treatment changed appropriately at an early stage."
The study was carried out on eight breast cancer patients who were being treated with chemotherapy until surgery.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance